Acylete

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acylete

What is Acylete? Definition and Classification

Property Description
Active Ingredient Aciclovir (INN)
Primary Forms Tablets, capsules, cream, intravenous injection
Pharmacological Class Antiviral Agent; Purine Nucleoside Analogue
General Purpose Managing specific human herpes virus infections
Origin Synthetic

Acylete is a name associated with the core medicine Aciclovir (INN), a foundational compound classified as an Antiviral Agent. This medication is a single-ingredient product, chemically identified as a synthetic purine nucleoside analogue of guanosine, meaning its manufactured structure closely mimics a natural genetic building block. This synthetic origin allows it to selectively target viral pathogens. Aciclovir acts as a cornerstone antiviral, having high selectivity for viral enzymes over human cellular enzymes.

Composition and Available Forms of Aciclovir

The product consists of the active ingredient Aciclovir combined with pharmaceutical excipients necessary for stability and delivery. The medicine is available in various dosage forms, allowing for both local and body-wide use. Forms for internal, or systemic, administration include tablets, capsules, oral suspension, and a powder for intravenous injection. The drug is also prepared for topical administration, such as a cream or ophthalmic ointment, to deliver the agent directly to a localized area. The versatility of administration routes is key to managing different presentations of the disease.

General Purpose: Managing Specific Viral Entities

The general therapeutic purpose of Acylete is to manage and limit the progression of diseases caused by specific human herpes viruses, including the Herpes simplex virus (HSV) and the Varicella zoster virus (VZV). As an antiviral agent, its function is not to eradicate the virus but to control its activity within the body. Aciclovir is used as a treatment option for these specific viral infections. By reducing the overall viral burden, the medicine helps the body contain the infection, thereby limiting the intensity and duration of the condition.

Regulatory References

  1. National Library of Medicine
  2. NIH MedlinePlus: Aciclovir Patient Information
  3. NIH Drug Information: Aciclovir Monograph

What side effects are possible with Acylete?

Possible side effects and safety information

The official safety profile of Aciclovir, the active ingredient in Acylete, outlines potential adverse effects classified by frequency and the body system affected. Most reported effects are generally reversible and categorized as Common or Very Common in regulatory documents from authorities such as the EMA and FDA. These frequently reported reactions primarily involve the gastrointestinal and nervous systems.


Frequency-Classified Adverse Reactions (Systemic Use)

Frequency Classification Examples of Reactions
Very Common Headache, dizziness
Common Nausea, vomiting, diarrhea, abdominal pains, fatigue, fever, skin rashes, pruritus (itching)
Rare Anaphylaxis, angioedema, reversible increases in liver-related enzymes and bilirubin
Very Rare Acute renal failure, hepatitis, jaundice, blood cell count changes (e.g., anemia), severe neurological reactions (e.g., confusion, convulsions)

Population-Specific and Safety Constraints

Adverse effects are grouped into system-organ classes including Nervous system disorders, Gastrointestinal disorders, Skin and subcutaneous tissue disorders, and Renal and urinary disorders. The safety data emphasizes that certain patients carry a higher risk for specific reactions. Older adults and individuals with impaired renal function are particularly noted to have an increased risk of concentration-dependent neurological side effects, such as confusion or agitation, due to altered drug clearance.

Regulatory safety statements advise that adequate hydration should be maintained, especially when the medicine is administered at high systemic doses. This is a crucial safety measure to mitigate the potential for the drug to affect kidney function, which is documented as a rare but serious adverse reaction.

Overdose and Emergency Response

The official regulatory profile for Acylete (Aciclovir) overdose documents severe manifestations that mandate immediate medical attention. Overdose is officially documented to present with signs of neurotoxicity, which can include agitation, confusion, hallucinations, somnolence, tremor, ataxia, and in severe cases, seizures and coma. Gastrointestinal effects such as nausea, vomiting, and diarrhea are also noted in the regulatory labels for oral overdose.

The most severe physiological consequence documented is acute renal failure, often resulting from the precipitation of the drug in the renal tubules, particularly following excessive intravenous exposure. This severe outcome may lead to anuria and has been observed in some reports to result in death. Elevated blood urea nitrogen (BUN) and serum creatinine are key laboratory findings associated with this toxicity.

Due to the potential for life-threatening outcomes, immediate medical attention must be sought if an overdose is suspected or if severe symptoms are observed. Patients must be managed under supervised care with close observation for signs of toxicity. Since no specific antidote is known, treatment relies on symptomatic and supportive care. Regulatory guidance states that Haemodialysis is an officially recognized procedure that significantly enhances the removal of Aciclovir and should be considered for managing symptomatic overdose. Elderly patients and individuals with impaired renal function are officially noted as populations with increased risk of developing these serious neurological and renal effects.

Therapeutic Uses of Acylete

Acylete Quick Facts

  • Therapeutic Domain: Management of specific viral infections.
  • Primary Uses: Genital herpes, shingles (herpes zoster), and chickenpox (varicella).
  • Relief: May help reduce the duration and severity of symptoms.

Acylete is an established prescription treatment used to manage infections caused by the herpes simplex virus (HSV) and varicella-zoster virus (VZV). The medication may be utilized for both initial and recurrent episodes in certain patient populations.

The main therapeutic applications of Acylete include the management of genital herpes and the treatment of herpes zoster, commonly known as shingles. Additionally, it is indicated for the management of varicella (chickenpox) in individuals who meet specific criteria.

Acylete can offer therapeutic benefits by supporting the patient's recovery process and may help lessen the severity of the infection. For example, in the context of recurrent genital herpes, it may be used to suppress the frequency of episodes. Its efficacy is generally maximized by the early initiation of treatment upon the appearance of signs or symptoms.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Acylete — Official Regulatory Information

This section outlines the eligibility criteria and formal exclusions for Acylete (Acyclovir/Aciclovir tablets) based strictly on authoritative government regulatory documentation, such as the FDA and EMA.


Absolute Contraindications (Must Not Use)

  • Hypersensitivity: The medicine is strictly contraindicated in patients with a known clinically significant allergy or hypersensitivity to aciclovir, valaciclovir (a prodrug of aciclovir), or any excipient (inactive component) present in the specific tablet formulation.

Conditional and Restricted Use Populations

  • Impaired Renal Function: Use is conditional and requires a mandatory dose adjustment based on creatinine clearance, as the drug is primarily eliminated through the kidneys. Close monitoring is necessary to prevent accumulation and related side effects.
  • Geriatrics (Elderly): Patients over 65 are considered likely to have reduced renal function and may require dose reduction and careful monitoring for neurological effects. Adequate hydration should be maintained.
  • Pregnancy and Lactation: Use during pregnancy or while breastfeeding requires a careful risk-benefit assessment by a clinician. The drug should be used only if the potential benefit justifies the potential, though undefined, risk.
  • Specific Comorbidities: Use should be with caution in patients with underlying neurological abnormalities, severe hepatic or electrolyte abnormalities, or significant hypoxia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Acylete (Aciclovir) is primarily eliminated by the kidneys, and its official interaction profile is characterized by interactions that affect renal clearance, as documented in regulatory labeling.

Pharmacokinetic and Pharmacodynamic Interactions

Certain medicinal products can compete with Aciclovir for the active renal tubular secretion pathway. This pharmacokinetic interaction results in increased systemic exposure (higher plasma concentrations and AUC) for one or both co-administered substances. Specific agents documented to reduce Aciclovir's renal clearance include Probenecid and Cimetidine. Co-administration with Mycophenolate Mofetil (MMF) and Tenofovir Disoproxil Fumarate (TDF) also leads to increased exposure of both drugs.

Additionally, a pharmacodynamic interaction exists with agents that affect the kidneys. Combining high intravenous doses of Aciclovir with other nephrotoxic medicinal products may result in an increased risk of renal impairment.

Substance and Population Considerations

The regulatory labels state that administration of Aciclovir with food does not significantly affect its absorption or systemic availability. No specific interactions are documented with alcohol, herbal products, or supplements. The official labeling notes that elderly patients are more susceptible to reduced renal function, which can lead to higher plasma concentrations of Aciclovir, increasing the potential for interaction with renally-excreted drugs.

Mechanism of Action

The action of Aciclovir (Acylete) is defined by its ability to interfere with the specific genetic replication machinery of the herpes virus, relying on the pathogen itself for activation.


The Mechanism of Viral-Dependent Activation and Selectivity

This domain explains how the drug utilizes the virus-specific enzyme, Viral Thymidine Kinase (TK), to initiate its conversion into the active form, a process known as selective phosphorylation. This dependence ensures the drug is primarily activated and trapped within the infected cells, localizing its inhibitory effect. The drug's activation is confined to infected cells, resulting in minimal interaction with host cellular processes.

DNA Chain Termination and Reduction of Viral Load

The fully activated metabolite, Aciclovir Triphosphate (ACV-TP), acts as an irreversible inhibitor of the Viral DNA Polymerase, causing immediate DNA chain termination when incorporated into the growing viral genome. This halting of the viral replication pathway directly prevents the assembly of new viral progeny, leading to a reduction in the systemic viral burden and restricting the progression of viral activity into adjacent cells.

Limitations Due to Enzyme-Driven Resistance

The drug's mechanism is constrained by mutations in the target viral enzymes; primarily, a deficiency in Viral Thymidine Kinase prevents the drug from being activated, and alterations in Viral DNA Polymerase reduce its binding affinity. These enzyme-driven failures can nullify the drug’s mechanism, resulting in the failure of the inhibitory mechanism against viral proliferation.

Dosage and Administration Information

How to Use Acylete: Administration Overview

Acylete (Aciclovir) is administered through several routes to address the systemic or localized nature of viral infections. The oral form, available as tablets and suspension, provides systemic action, while intravenous (IV) injection is reserved for more severe cases or hospital settings. For localized infections, topical cream and ophthalmic ointment are used.


Standardized Dosing and Frequency

Acylete is utilized according to specific dosing schedules for various usage contexts.

Usage Context Standard Adult Dose Administration Frequency
Oral Acute Treatment (e.g., Shingles) 800 mg per dose 5 times daily
Oral Suppressive Therapy 400 mg per dose Twice daily
Intravenous Infusion 5 mg/kg to 10 mg/kg Every 8 hours

Administration Requirements

Courses of therapy, whether for acute episodes or long-term suppression, follow standardized durations. Acute treatment typically involves a fixed duration of 5 to 10 days. Treatment is intended to be initiated at the earliest sign or symptom of the infection.

When taking the oral forms, the medicine may be consumed without regard to meals but must be taken with adequate fluid intake. This requirement for maintaining hydration is also a procedural condition for IV administration, where the solution must be diluted and infused slowly over a minimum of one hour. Furthermore, dose and frequency are modified for patients with known renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Acylete

Evidence for Use in Genital Herpes (HSV-2)

The research exploring the use of Acylete for initial and recurrent outbreaks of genital herpes includes Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies primarily focused on two distinct approaches: short-term use during an acute outbreak (episodic treatment) and continuous use over extended periods (suppressive therapy).

In trials assessing short-term symptom patterns, researchers monitored outcomes related to physical discomfort, such as the time required for lesions to heal, and the cessation of viral activity. Patterns of measurements related to the time to clinical resolution were observed. For suppressive therapy, studies observed the patterns related to a lower reported frequency of recurrence episodes while the observation was in progress over periods lasting up to one or two years.

Evidence for Use in Herpes Zoster (Shingles) (VZV)

Research examining the studied application of Acylete for acute Herpes Zoster (shingles) was primarily conducted using Randomized Controlled Trials (RCTs), and the findings have been aggregated in various Meta-analyses. Studies monitored outcomes related to the visible progression of the condition, such as time to crusting of the skin rash, and the duration of acute pain experienced during the infection.

Studies reported how symptoms evolved in the observed populations, indicating patterns related to an accelerated timeline for the rash to heal. However, when research explored the long-term outcome of Postherpetic Neuralgia (PHN)—a condition marked by functional limitations—the findings were mixed across various aggregated datasets. The certainty remains low for a consistent, measured outcome on PHN across all studied groups.

Understanding Research Gaps and Uncertainty

The overarching evidence landscape contributes to understanding symptom patterns, but several research limitations are acknowledged in regulatory reviews and scientific literature. Data are still emerging, and research provides insight into short-term changes, but long-term effects are not fully established, particularly concerning the durability of any observed patterns once the intervention is withdrawn.

For certain groups, such as low-risk children with varicella, the measured change in outcomes was often modest, which regulatory bodies have noted. Findings were also mixed across studies related to the prevention of PHN, and comparative evidence is lacking regarding the long-term emergence of resistant viral strains.

Key Studies & References Acyclovir - StatPearls - NCBI Bookshelf (Review of Indications, Mechanism, and Dosing)

Frequently Asked Questions (FAQ)

Common questions about Acylete (FAQ)

Q: How quickly does Acylete usually start working after the first time taking it?

Official information emphasizes the importance of starting Acylete treatment as soon as the first sign or symptom of the viral infection appears. For example, in studies for conditions like shingles, treatment was often initiated within one day of the rash starting. Regulatory guidance focuses on early initiation to align with the patterns observed in clinical studies, rather than providing a specific timeline for when the medicine is first noticed by the user.

Q: How long does the effect of Acylete last once it starts working?

The duration of the drug’s presence in the bloodstream is often described by its plasma half-life, which is how long it takes for half of the dose to be cleared from the body. For Acylete (aciclovir), this is generally reported to be approximately 2.5 to 3.3 hours in individuals with typical kidney function. This clearance rate is reflected in the official administration frequency.

Q: Can children or teenagers be prescribed Acylete?

Yes, Acylete can be used to manage certain viral infections in children and adolescents, including infants and newborns. Official regulatory documentation includes specific usage information for pediatric patients. For instance, treatment protocols for children 2 years of age and older weighing less than 40operatornamekg typically include weight-based dosing. Decisions regarding use in very young children are made by a prescriber.

Q: Does Acylete affect birth control or fertility?

Official prescribing information does not generally list a direct interaction with hormonal methods of birth control. However, studies in animals exposed to high doses have indicated potential effects on male fertility. Information regarding the drug’s use during pregnancy and breastfeeding is provided in official labels, but the relevance of these animal findings to human fertility is not fully established.

Q: What happens to Acylete in the body after it is taken?

After taking the medicine orally, Acylete is partially absorbed into the system and is distributed widely throughout the body. The drug is primarily removed, or eliminated, from the body by the kidneys, mostly unchanged, through the urine. The rate at which the kidneys clear the drug is a key factor in how frequently it needs to be administered.

Q: Are there known genetic factors that affect how Acylete works?

Official regulatory documents describe that the development of resistance to Acylete is due to changes, or mutations, that occur in the viral enzymes themselves. These changes in the virus's genetics prevent the drug from activating properly or binding effectively. Official documentation does not typically address how a patient's own inherited genetic factors influence the drug's activity.

Q: Does taking Acylete affect blood pressure or heart rate?

The common side effects reported for Acylete do not usually include changes to blood pressure or heart rate. However, post-marketing safety data does occasionally mention less common reactions such as low blood pressure (hypotension) or chest pain/palpitations. These are generally grouped under less frequent or serious adverse reactions in regulatory reports.

Q: Does Acylete cause dependency or withdrawal symptoms?

Acylete is classified by regulatory authorities as an antiviral agent. Official drug warnings and classifications do not indicate that the drug causes physical dependency or leads to withdrawal symptoms upon cessation of use.

Q: Is Acylete a controlled substance or addictive?

No, Acylete (aciclovir) is classified as a prescription antiviral medicine. It is not listed as a scheduled controlled substance by major government regulatory agencies, nor is it described as having addictive properties.

Q: Is Acylete a new drug, or has it been around for a while?

Aciclovir, the active ingredient in Acylete, is a well-established medication. The drug was initially discovered in the 1970s and received its first major regulatory approval for treating herpes infections in the United States in 1982. It is a well-established medication with regulatory approval dating back to the early 1980s.

Q: Can Acylete be taken at the same time as antacids?

Antacids are not one of the specific medications that official product labels list as having a significant interaction with Acylete. Regulatory warnings focus on other types of medicines that affect kidney function, such as Probenecid. Official documentation does not typically address the concomitant use of antacids.

Q: Is it common for people to need a dosage adjustment after starting Acylete?

Official documentation describes that adjustments to the dose are necessary for people with pre-existing impaired kidney function. Dose changes are also often required for older adults due to typical age-related changes in kidney function. For the majority of individuals with normal kidney function, the official dosing schedule is followed.

Q: What are the storage requirements for Acylete?

Acylete must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), in its original container, and kept away from light and moisture. Liquid forms of the medicine may carry specific warnings not to freeze or refrigerate to prevent instability.

How should Acylete be stored and disposed of?

How to Store and Dispose of Acylete (Acyclovir)

Official regulatory guidelines mandate specific conditions for storing and disposing of Acylete to ensure its stability and maintain safety.

Storage Requirements

Acylete tablets must be stored at Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be kept in its original, tightly closed container and protected from light and moisture. Certain formulations, such as the oral suspension, are explicitly labeled with a do not freeze or refrigerate warning. All forms of Acylete must be stored out of the reach of children.

Disposal Instructions

Unused, expired, or unwanted Acylete must be disposed of according to local government regulations for medication. It is generally mandated not to dispose of the product by flushing it down a toilet or pouring it down a drain. Any waste material should be handled in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acylete found in:

A-Z Index: